Daratumumab clinical trials
Also written Darzalex, JNJ-54767414 and HuMax-CD38.
Includes 12 studies of Daratumumab and Hyaluronidase-fihj.
Related medicines add 3 studies
Counted the way a researcher would: Daratumumab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses daratumumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the daratumumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Nov 2015 · DARZALEX · BLA 761036 (FDA, Drugs@FDA)
- European Union
- 20 May 2016 · Darzalex · EMEA/H/C/004077 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Brand
- Darzalex
- 78
In one entry with another drug
Given together, or one or the other
Biosimilars
- HLX15
- 1
Studies by the year they started
219 studies that test it; most in 2019 (26)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 8 |
| 2016 | 8 |
| 2017 | 23 |
| 2018 | 25 |
| 2019 | 26 |
| 2020 | 17 |
| 2021 | 26 |
| 2022 | 20 |
| 2023 | 19 |
| 2024 | 16 |
| 2025 | 17 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 46 · Other 173
Janssen Research & Development, LLC (24) · Mayo Clinic (11) · M.D. Anderson Cancer Center (9) · Institute of Hematology & Blood Diseases Hospital, China (9) · Hellenic Society of Hematology (6) · Memorial Sloan Kettering Cancer Center (5) · City of Hope Medical Center (5) · Stichting European Myeloma Network (5)
Often tested with
Tested in the same studies.
Dexamethasone (70) · Lenalidomide (36) · Bortezomib (25) · Carfilzomib (18) · Pomalidomide (17) · Ixazomib (11) · Cyclophosphamide (9) · Melphalan (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 23 phase 3 studies under way
Daratumumab is the comparator. A study of two new drugs counts under both.
- 5Belantamab mafodotin · GlaxoSmithKline, PrECOG, LLC. · next primary completion Apr 2031
- 2Linvoseltamab · Regeneron Pharmaceuticals · next primary completion Jul 2033
- 2Etentamig · AbbVie · next primary completion Feb 2033
- 1Equecabtagene autoleucel · Nanjing IASO Biotechnology Co., Ltd. · next primary completion Aug 2027
- 1Anitocabtagene autoleucel · Kite, A Gilead Company · next primary completion Jul 2028
- 1QLS4131 · Qilu Pharmaceutical Co., Ltd. · next primary completion Dec 2029
- 1CM336 · Keymed Biosciences Co.Ltd · next primary completion May 2030
- 1Lumrotatug · Keymed Biosciences Co.Ltd · next primary completion May 2030
Reaching primary completion within a year · 30, 2 in phase 3
Studies that test daratumumab, phase 3 first.
- Nov 2026Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisPhase 3 · The First People's Hospital of Changzhou
- Mar 2027A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaPhase 3 · Celltrion
- Dec 2026Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in GlioblastomaPhase 1/2 · West Virginia University
- Dec 2026Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MMPhase 2 · Alliance Foundation Trials, LLC.
- Dec 2026Daratumumab in HLA Desensitization Prior to TransplantationPhase 2 · Barry A. Boilson
- Dec 2026Risk Stratification and MRD-driven Maintenance for MM After ASCTNot applicable · Peking University People's Hospital
- Jan 2027Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabPhase 2 · Weill Medical College of Cornell University
- Jan 2027Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)Phase 2 · University of Alabama at Birmingham
- Jan 2027STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMAPhase 4 · University of Turin, Italy
- Feb 2027A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple MyelomaPhase 2 · University of Miami
Studies
Open first, then newest update. How each study uses daratumumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 219
- Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering MyelomaRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT03937635Written as Daratumumab
- Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLRecruitingPhase 2Eastern Cooperative Oncology GroupNCT05289687Written as Daratumumab / Hyaluronidase Injection
- The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaRecruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07287228Written as Daratumumab
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingPhase 1City of Hope Medical CenterNCT06287944Written as Daratumumab
- Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingPhase 1City of Hope Medical CenterNCT05363111Written as Daratumumab
- Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell DisordersRecruitingPhase 1/2University of Maryland, BaltimoreNCT07075510Written as Daratumumab Injection
- A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic LymphomaRecruitingEarly Phase 1AIDS Malignancy ConsortiumNCT04139304Written as Daratumumab
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingPhase 3PfizerNCT05623020Written as Daratumumab
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)RecruitingPhase 1/2AbbVieNCT06953960Written as Daratumumab
- Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple MyelomaRecruitingPhase 2Tata Memorial CentreNCT07891923Written as Daratumumab (Intravenously)
- Daratumumab in Primary Antiphospholipid SyndromeRecruitingPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05671757Written as Daratumumab
- Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseRecruitingPhase 2National Cancer Institute (NCI)NCT05907759Written as Daratumumab SC
- Daratumumab in HLA Desensitization Prior to TransplantationEnrolling by invitationPhase 2Barry A. BoilsonNCT05300451Written as Daratumumab and hyaluronidase-fihj
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06398457Written as Darzalex Faspro (Daratumumab and hyaluronidase-fihj)
- Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA TrialRecruitingPhase 2Mayo ClinicNCT05898646Written as Daratumumab
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingPhase 2Hackensack Meridian HealthNCT04661137Written as Daratumumab
- The Effect of Daratumumab in Patients With Monoclonal Gammopathy of Renal Significance (MGRS) in FinlandRecruitingPhase 2Helsinki University Central HospitalNCT06889948Written as Daratumumab
- Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & LymphomaRecruitingPhase 1New York Medical CollegeNCT04972942Written as Daratumumab
- Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.RecruitingPhase 2Fondazione Italiana Linfomi - ETSNCT04915248Written as Daratumumab
- Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune ThrombocytopeniaRecruitingPhase 4Institute of Hematology & Blood Diseases Hospital, ChinaNCT07788456Written as Daratumumab
See all 219 studies that test daratumumab →
Given beside what is tested · 99 — daratumumab is usual care or a partner of the new treatment
- Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT04566328Written as Daratumumab and Hyaluronidase-fihj
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingPhase 3University of LeedsNCT07649525Written as Daratumumab
- Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney FailureRecruitingPhase 2Eastern Cooperative Oncology GroupNCT07085728Written as Daratumumab-hyaluronidase
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Daratumumab
- A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsRecruitingPhase 1Regeneron PharmaceuticalsNCT05137054Written as Daratumumab
- A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant EligibleNot yet recruitingPhase 3Janssen Research & Development, LLCNCT07903272Written as Daratumumab
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingPhase 2National Cancer Institute (NCI)NCT06948084Written as Daratumumab and Recombinant Human Hyaluronidase
- FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1Medical College of WisconsinNCT07221032Written as Daratumumab 16 mg/kg
- A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07222761Written as Daratumumab
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingPhase 3Janssen Research & Development, LLCNCT05552222Written as Daratumumab
- A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not PlannedRecruitingPhase 3Janssen Research & Development, LLCNCT07665450Written as Daratumumab
- Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null PhenotypeRecruitingPhase 1Andrew Hantel, MDNCT07341867Written as Daratumumab
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)RecruitingPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06615479Written as Daratumumab
- CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07830485Written as Daratumumab
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingPhase 1/2BeOne MedicinesNCT04973605Written as Daratumumab
- Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT07605416Written as Daratumumab and Recombinant Human Hyaluronidase
- Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple MyelomaNot yet recruitingPhase 2/3Alliance for Clinical Trials in OncologyNCT07887984Written as Daratumumab and Recombinant Human Hyaluronidase
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Kite, A Gilead CompanyNCT07887672Written as Daratumumab
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1Genentech, Inc.NCT04910568Written as Daratumumab
- A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in CombinationsRecruitingPhase 1/2AbbVieNCT06892522Written as Daratumumab
Showing 20 of 99.
As the comparator · 32 — what is tested is compared with daratumumab
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131Not yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07933432Written as Daratumumab Injection (Subcutaneous Injection)
- Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingPhase 3PrECOG, LLC.NCT07285239Written as Arm B: Daratumumab Hyaluronidase
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingPhase 3Hoffmann-La RocheNCT07555938Written as Daratumumab
- A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)RecruitingPhase 3Regeneron PharmaceuticalsNCT07393282Written as Daratumumab
- Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3Keymed Biosciences Co.LtdNCT07910903Written as Daratumumab
- Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain AmyloidosisNot yet recruitingPhase 3Regeneron PharmaceuticalsNCT07901725Written as Daratumumab
- Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple MyelomaRecruitingPhase 3Canadian Cancer Trials GroupNCT06182774Written as Daratumumab
- A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)RecruitingPhase 3AstraZenecaNCT07391657Written as Daratumumab
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07623798Written as Daratumumab Injection (Subcutaneous Injection)
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisNot yet recruitingPhase 3AbbVieNCT07793422Written as Daratumumab
- A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)RecruitingPhase 3BiocadNCT07742215Written as BCD-248 + daratumumab
- A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable DiseaseNot yet recruitingPhase 3Polish Myeloma ConsortiumNCT07740486Written as Daratumumab (Subcutaneously)
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaNot yet recruitingPhase 3AbbVieNCT07728188Written as Daratumumab
- A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)RecruitingPhase 3GlaxoSmithKlineNCT06679101Written as Daratumumab
- A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT07452198Written as Daratumumab
- A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male SubjectsNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07400744Written as Darzalex
- A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaNot yet recruitingPhase 3Shanghai Henlius BiotechNCT06895512Written as Darzalex
- A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy AdultsRecruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT06371534Written as DARZALEX FASPRO®
- To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple MyelomaNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT06742138Written as DARZALEX FASPRO®
- A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple MyelomaRecruitingPhase 3BiocadNCT06296121Written as Darzalex
Showing 20 of 32.
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic AnemiaNov 6, 2026NCT07287228
Results posted2
Newly registered2
Codes
What other systems call daratumumab · ClinicalTrials.gg INT005784
- MeSH (NLM) C556306daratumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4Z63YK6E0EDARATUMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1721947Confirmed FDA, Wikidata
- Wikidata Q5222113daratumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C74007DaratumumabOne source FDA
- DrugBank DB09331One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C556306 | daratumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4Z63YK6E0E | DARATUMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1721947 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5222113 | daratumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C74007 | Daratumumab | One source FDA |
| DrugBank | DB09331 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.